CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
利用 CAR NK 细胞克服肿瘤免疫治疗耐药的新策略
英文原题：Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells.
查看英文原题
Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管免疫治疗面临障碍，嵌合抗原受体（CAR）工程化自然杀伤（NK）细胞的出现正在开辟新途径，并可能很快成为优于CAR-T 细胞的首选方案。CAR NK引入多种细胞毒性机制，为对抗肿瘤免疫治疗耐药提供了新策略。同时，NK细胞归巢的改善以及基因编辑CAR NK细胞疗法为克服癌症免疫治疗中的挑战提供了有前景的途径。本综述探讨了耐药机制和工程化策略，通过改善NK细胞向肿瘤部位的归巢和迁移来增强CAR NK细胞功能，并强调来自临床前和临床研究的见解。
展开英文摘要原文
While immunotherapy faces obstacles, the emergence of chimeric antigen receptor (CAR) engineered natural killer (NK) cells is paving new ways and might become a preferred option over CAR T cells very soon. CAR NK introduce diverse cytotoxic mechanisms offering novel strategies to combat tumor immunotherapy resistance. Concurrently, improvements in NK cell homing and gene-edited CAR NK cell therapy offer promising avenues for overcoming challenges in cancer immunotherapy.
Our review addresses resistance mechanisms and engineering strategies to enhance CAR NK cell functionality by improving NK cell homing and migration to tumor sites, emphasizing insights from preclinical and clinical studies.
论文信息
- 作者
- Guo JH、Afzal A、Ahmad S、Saeed G、Rehman A、Saddozai UAK、Liu L、Guo SH
- 单位
- Department of Oncology, The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, Henan, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40510336 · DOI 10.3389/fimmu.2025.1550652
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →